


# Lipids Point-of-Care Testing Clinical Tool



**PLEASE NOTE: Only information related to a standard lipid panel (TC, TG, HDL-C, LDL-C, non-HDL-C) are included in this resource in alignment with the scope of practice of pharmacists as per O. Reg. 202/94 under the *Pharmacy Act, 1991*.**

## ABBREVIATIONS:

**ACR:** albumin-to-creatinine ratio; **ApoB:** apolipoprotein B; **ASCVD:** atherosclerotic cardiovascular disease; **BMI:** body-mass index; **CCS:** Canadian Cardiovascular Society; **CKD:** chronic kidney disease; **CLEM:** Cardiovascular Life Expectancy Model; **COPD:** chronic obstructive pulmonary disease; **CV:** cardiovascular; **CVD:** cardiovascular disease; **eGFR:** estimated glomerular filtration rate; **FRS:** Framingham Risk Score; **HDL-C:** high-density lipoprotein cholesterol; **HIV:** human immunodeficiency virus; **LDL-C:** low-density lipoprotein cholesterol; **Lp(a):** lipoprotein(a); **OHIP:** Ontario Health Insurance Plan; **PCSK9:** proprotein convertase subtilisin/kexin type 9; **POCT:** point-of-care test; **TC:** total cholesterol; **TG:** triglycerides

## DISCLAIMER:

The Ontario Pharmacists Association (OPA) provides this material to pharmacy professionals for informational purposes only and is intended to assist pharmacy professionals with initiating discussions with patients about point-of-care testing but does not replace professional judgment and responsibilities. It is provided without warranty of any kind by OPA and OPA assumes no responsibility for any errors, omissions or inaccuracies therein. The decision for use and application of this document is the responsibility of the user. OPA assumes no liability for such use and application or any resulting outcomes. It is the responsibility of the pharmacy professional to use professional judgment in evaluating this material in light of any relevant clinical or situational data. It is intended to supplement materials provided by regulatory authorities, and should there be any discrepancies, municipal, provincial, and federal laws, policies and guidelines shall prevail. This information is up to date as at the date of publication. Pharmacy professionals are encouraged to confirm information with additional resources.

## REFERENCES:

- i. Pearson, G. J., Thanassoulis, G., Anderson, T. J., Barry, A. R., Couture, P., Dayan, N., Francis, G. A., Genest, J., Grégoire, J., Grover, S. A., Gupta, M., Hegele, R. A., Lau, D., Leiter, L. A., Leung, A. A., Lonn, E., Mancini, G., Manjoo, P., McPherson, R., Ngui, D., ... Wray, W. (2021). 2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults. *The Canadian journal of cardiology*, 37(8), 1129-1150. <https://doi.org/10.1016/j.cjca.2021.03.016>
- ii. Paquette, M & Bernard, S. Dyslipidemias. (2022) *Therapeutic Choices*. Canadian Pharmacists Association. Accessed June 15, 2022. <http://www.myrxtx.ca>
- iii. Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., Goldberg, R., Heidenreich, P. A., Hlatky, M. A., Jones, D. W., Lloyd-Jones, D., Lopez-Pajares, N., Ndumele, C. E., Orringer, C. E., Peraltta, C. A., Saseen, J. J., ... Yeboah, J. (2019). 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation*, 139(25), e1082-e1143. <https://doi.org/10.1161/CIR.0000000000000625>
- iv. Rosenson, R. S. (2021). Patient Education: High cholesterol and lipids (Beyond the basics). *UpToDate*. Retrieved May 11, 2022, from <https://www.uptodate.com/contents/high-cholesterol-and-lipids-beyond-the-basics>
- v. Ministry of Health: Ontario Health Insurance Plan: Laboratories and Diagnostics Branch. (2023, July 5). *Schedule of Benefits for Laboratory Services*. Government of Ontario. Accessed September 19, 2024. <https://www.ontario.ca/files/2024-01/moh-ohip-schedule-of-benefits-laboratory-services-2024-01-24.pdf>
- vi. Florkowski, C., Don-Wauchope, A., Gimenez, N., Rodriguez-Capote, K., Wils, J., & Zemlin, A. (2017). Point-of-care testing (POCT) and evidence-based laboratory medicine (EBLM) - does it leverage any advantage in clinical decision making?. *Critical reviews in clinical laboratory sciences*, 54(7-8), 471-494. <https://doi.org/10.1080/10408363.2017.1399336>
- vii. Nichols, J. H. (2020). Chapter 19 - Point-of-care testing. In W. Clarke & M. A. Marzinko (Eds.), *Contemporary Practice in Clinical Chemistry (Fourth Edition)* (pp. 323-336). Academic Press. <https://doi.org/10.1016/B978-0-12-815499-1.00019-3>
- viii. Government of Canada. (2021, March 19). *Safe Medical Devices in Canada*. Accessed May 11, 2022. <https://www.canada.ca/en/health-canada/services/drugs-health-products/medical-devices/activities/fact-sheets/safe-medical-devices-fact-sheet.html>